Comerica Bank’s Protagonist Therapeutics PTGX Stock Holding History

Comerica Bank’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.14M	Sell	13,005 -3,390	-21%	-$277K	﹤0.01%	1438
2025 Q3	$1.09M	Sell	16,395 -4,896	-23%	-$278K	﹤0.01%	1499
2025 Q2	$1.18M	Buy	21,291 +1,050	+5%	+$50.4K	﹤0.01%	1436
2025 Q1	$979K	Sell	20,241 -317	-2%	-$13.3K	﹤0.01%	1509
2024 Q4	$794K	Sell	20,558 -346	-2%	-$15.1K	﹤0.01%	1683
2024 Q3	$941K	Buy	20,904 +20,634	+7,642%	+$834K	﹤0.01%	1580
2024 Q2	$9.37K	Hold	270	–	–	﹤0.01%	3172
2024 Q1	$7.82K	Buy	270 +43	+19%	+$1.17K	﹤0.01%	3235
2023 Q4	$5.21K	Buy	+227	New	+$3.97K	﹤0.01%	3309

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Comerica Bank's PTGX Position: Q4 2025 in Review

Comerica Bank reduced its Protagonist Therapeutics (PTGX) stake by 21% in Q4 2025, selling an estimated $277K and leaving 13,005 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1438.

Comerica Bank first reported a position in PTGX in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.18M in Q2 2025. 314 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

Comerica Bank held 13,005 shares of Protagonist Therapeutics worth $1.14M as of Q4 2025.
Comerica Bank sold 3,390 Protagonist Therapeutics shares in Q4 2025, an estimated $277K.
Protagonist Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #1438 holding.
Comerica Bank first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 9 quarters since.
Comerica Bank's Protagonist Therapeutics position peaked at $1.18M in Q2 2025.
314 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.